Iwaki City, Fukushima Prefecture (about 200 Kms from Tokyo) in an industrial area. It has the warmest climate in the Tohoku region and is rich in nature with mountains and the sea. Iwaki city is famous for multiple attractions including hot springs.
Tokyo Tanabe was the original developer of UDCA in Japan in the 1950’s and the Iwaki plant was established after multiple acquisitions within Mitsubishi Tanabe group in the 1980’s. In May 2022 the site was acquired by ICE Pharma. We are proud of its long heritage of high quality stable supply to Japanese and international customers.
ICE Japan plant is dedicated to the production of high-quality ursodeoxycholic acid. It is an integrated manufacturing unit starting from cholic acid raw material. The site is approved for supply to the Japanese, US, European and Chinese markets.
Ursodeoxycholic acid is an API used for the treatment of primary biliary cirrhosis (PBC), dissolution of radiolucent gallstones in patients with a functioning gallbladder, and treatment of hepatobiliary disorders associated with cystic fibrosis in pediatric patients.
Dr. Kailash Sharma
Dr. Kailash Sharma has 25+ years of professional experience in managing core functions in all phases of the drug development cycle for multinational pharmaceutical companies. This includes experience in managing manufacturing and a track-record as General Manager. Professional competencies include strong scientific knowledge combined with an in-depth training in business principles and strategic business development. Dr Sharma is fluent in Japanese and English.
1-2 Keiseisaku, Jobanmisawamachi, Iwaki City, Fukushima Prefecture 971-8136
Get in touch with ICE Japan today